Dr Patrick AUGUSTE (INSERM Bordeaux)

For more than 20 years, this teacher-researcher has been working on cancer. And it's been almost 10 years since he went to kidney cancer or renal cell carcinoma. By joining the team of Dr Christophe Grosset (Inserm, MiRCaDe team), he wanted to use his experience and take a new step forward by working on childhood cancer. He is the initiator of an ambitious project, which involves several surgeons, doctors and international researchers, on the study of nephroblastoma (or Wilms tumor) in children, co-funded by the association Eva pour la vie and Aidons Marina ...

Dr Patrick Auguste you are in charge of the study of Wilms tumor in the MiRCaDe team led by Dr Christophe Grosset. Can you tell us more about the project and the motivations that led you to work on childhood cancer?

For more than 20 years I have been working on cancer, more specifically in adults. And it's been almost 10 years since I went to kidney cancer or renal cell carcinoma. By joining the team of Dr Christophe Grosset (Inserm unit 1035, MiRCaDe team), I wanted to climb a new level in my career and work on childhood cancer without however moving away from what I knew, it is ie renal carcinoma. I remain convinced that the treatments for cancer in children must be completely different from those in adults. For that we must find new targets for these treatments, and we must therefore understand how childhood cancers and in particular, in my case, how nephroblastoma or Wilms tumor develops.

Wilms tumor is the main kidney tumor in children. It develops from the developing kidney and affects 1 in 100,000 children, which represents 100 cases per year in France. It is generally well cared for but in a little less than 10% of cases it results in the death of the patient mainly because of metastases. 10% of patients, it doesn't seem like much, but it's still too much for young children. In addition, chemotherapy and, possibly, radiotherapy are heavy for a young child and can be disabling afterwards.

The aim of the project is to characterize other therapeutic targets in high-risk Wilms tumors, ie tumors that can lead to the death of the child. For this we will identify the proteins that are specifically present in high risk tumors and which are absent in lower risk tumors. These proteins, present only in high-risk tumors, could subsequently be studied and targeted in new therapies.

Did you encounter any technical difficulties in launching this project?

The main difficulties lie in the study of future target proteins. For this, it is absolutely necessary to start studying them in the laboratory on Wilms tumor cells. However, there is only one commercially accessible cell line. This very certainly reflects a great difficulty in obtaining cells in culture from tumors. It is therefore proposed to obtain new cell lines from tumors. For this a technique recently used with success for obtaining a new Wilms tumor line will be used. So our project will also be used to obtain cell models which will then be accessible to the scientific community.

The characterization of the proteins specifically expressed in high-risk Wilms tumors will be carried out by a new technology developed at the University of Bordeaux by Dr Anne-Aurélie Raymond and Fréderic Saltel. Wilms tumors, like many pediatric cancers, are rare tumors and very often laboratories only have blocks of tumors that have been firmly fixed for the pathologist to make a diagnosis. The problem with binding is that it modifies the proteins and that it is subsequently impossible to characterize them. In this new technique, changes in proteins due to binding are reversed and it is subsequently easy to identify the proteins by a method called mass spectrometry. Once these proteins are identified, with the help of cultured cells, we can study the role of these proteins in high risk Wilms tumors. The aim, of course, is then to be able to inhibit the activity of these proteins in order to be able to kill the cells and therefore destroy the tumor.

Can you introduce us to the team that will work with you on the project?

I am part of an Inserm unit in Bordeaux (U1035), headed by Dr Alain Taïeb, who works on cancer mainly in adults. This unit is divided into several teams, including the MiRCaDe team to which I belong. This team, led by Dr Christophe Grosset, works mainly on pediatric cancers and more particularly on hepatoblastoma, infiltrating glioma of the brainstem and, now, Wilms tumor. The Wilms tumor project is international and will bring together people with different and complementary specialties. It will bring together, in addition to myself, a doctoral student from the University of Bordeaux and the team that developed the technique for identifying proteins. It will also be done in collaboration with a team of doctors in Seville (Spain), more particularly by Drs de Alava and Ramirez-Villar. Dr de Alava is the pathologist who monitors all kidney cancer diagnoses in Spain and Dr Ramirez-Villar is a member of the European Committee for Childhood Kidney Cancer (SIOP RTSG), a committee that defines the treatment of all pediatric cancers of the kidney. They are the ones who will provide the tumor blocks, the cells to be cultured and who will participate in the characterization of the role of the proteins characterized in high-risk tumors.

Did you encounter any financial or administrative difficulties in launching this project? What will Eva's financial support for life allow you to do?

In all projects, including this one, the hardest part is finding the money to start. The risks are higher when starting a project compared to an already established project. But it is also the risks that lead to new discoveries. The funding provided by Eva for Life will allow us to finance the characterization of proteins in high risk tumors. It is therefore highly crucial and will allow us to characterize proteins that can serve as therapeutic targets in order to treat high-risk Wilms tumors.

En téléchargement

Download the document



Eva pour la vie & Grandir sans cancer ont, de par leur engagement financier, fortement accéléré le démarrage d’une start-up du médicament liée à la volonté de développer une petite molécule innovante pour le traitement du glioblastome, une tumeur du cerveau de l’adulte et de l’enfant très agressive et généralement incurable. Les dirigeants de cette start-up nous expliquent leurs travaux, perspectives et l'importance de favoriser le développement de petites sociétés axées sur des cancers rares, en particulier les cancers pédiatriques les plus agressifs ...

Dr Fabienne MEGGETTO (INSERM Toulouse)

Dr Fabienne Meggetto is research director at INSERM Toulouse, within a team of excellence whose research work focuses on lymphomas in children. The Eva pour la vie association has decided to provide aid of 50,000 euros for the start of an ambitious and transversal project, which could make it possible to find new therapeutic avenues for lymphomas with a poor prognosis, but also, others. solid tumors such as neuroblastoma. ...

Dr Sébastien APCHER (IGR, Villejuif)

Le Dr Sébastien APCHER est un chercheur INSERM responsable de l’équipe « Epitopes non-conventionnels et réponse immunitaire anti-cancéreuse » à l’INSTITUT GUSTAVE ROUSSY de Villejuif. Il a décidé d’orienter ses travaux de recherche sur les cancers de l’enfant. Eva pour la vie soutient financièrement cette équipe, d'une façon durable. Interview ...

Dr Max PIFFOUX (Center Léon Bérard, Lyon)

Doctor Max PIFFOUX - under the responsibility of the "Apoptosis and cancer" team coordinated by Aurélie DUTOUR at the CLB - is the scientific manager of the following research project: "Autophagic induction as a booster of response to immunotherapies: trial of a new therapeutic class, calorie restriction mimetics, in the pediatric osteosarcoma model ". Eva pour la vie & Aidons Marina have decided to co-finance the launch of this project, by providing a grant of 40,000 euros.

Dr Olivia FROMIGUE (Institut Gustave Roussy)

Resistance to treatment is a major clinical problem, in particular in the case of osteosarcomas, bone tumors affecting children or adolescents. Indeed, chemotherapy, associated with surgery, is the central pillar of current treatment. However, many osteosarcomas are or become resistant to these antiproliferative drugs. Recurrences and / or the appearance of metastases are then frequent. 2 out of 5 patients cannot be cured! Osteosarcoma is therefore a pediatric cancer with a poor prognosis for which it is absolutely necessary to identify ways to counteract resistance to treatment in order to improve the chances of recovery for patients.

Dr Christophe GROSSET (INSERM Bordeaux)

Since 2012, Dr Christophe Grosset has been studying hepatoblastoma, a liver tumor that affects very young children. Today, the main difficulty is to treat patients suffering from metastases or from an inoperable tumor resistant to treatment. With the support of the Eva pour la vie association, the team has set up a new model of hepatoblastoma in the chick embryo which makes it possible to test the effectiveness of new therapeutic molecules (such as microRNAs) and of facilitate the study of these tumors in the laboratory. It has also shown the value of a drug already used in the treatment of certain leukaemias, to treat children with very aggressive liver cancer.

Dr Martin HAGEDORN (INSERM Bordeaux)

Since September 2014, Dr Martin Hagedorn has been leading a team of researchers (Caroline CAPDEVIELLE , Farah RAHAL, Justine CHARPENTIER and Mélissa MENARD) which devotes its research work to the identification of new therapeutic targets in brainstem tumors and to the improvement of its treatment methods. Work recognized by several European scientific teams & experts.


The preclinical research project of Dr Alliana Schmid's team focuses on the treatment of pulmonary metastases from osteosarcoma by combinations of immunotherapy.

The aim of this project, which is unique in France, is to evaluate, in a preclinical model of pulmonary metastases from osteosarcoma - a cancer with a poor prognosis which particularly affects adolescents - the effects of a treatment combining two complementary immunotherapy strategies. The Eva pour la vie association is providing funding of 50,000 euros over 3 years, representing the entire cost of this project.

Dr Eddy PASQUIER (CNRS Marseille)

Dr Pasquier's research work mainly focuses on the repositioning of drugs which consists of testing, in new therapeutic indications, drugs already approved by the health authorities. The aim of this work is to identify new therapeutic targets for the most difficult to treat cancers and thus improve the care of patients suffering from these aggressive forms and refractory to treatment . In particular, pediatric cancers (neuroblastoma), brain tumors affecting children as well as adults (glioblastoma, medulloblastoma) as well as certain rare forms of cancer (angiosarcoma).


The work of the INSERM team co-directed by Dr Marie Castets (CR1 Inserm, HDR) and Dr Jean-Yves Blay (PUPH, HDR) focuses on cell death and cancers. Thanks to the support of Eva pour la Vie (55,000 euros) and other associations, this team is currently developing these lines of research on rhabdomyosarcomas, osteosarcomas and neuroblastomas ...

Prof. Sébastien PAPOT (University of Poitiers)

At the end of 2018, the Nouvelle Aquitaine region agreed to co-finance with Eva for life the research project "Biological and preclinical studies of new anticancer agents, including some targeting EZH2 / PRC2, in the treatment of highly proliferating hepatoblastoma", led by Prof. Papot and Dr Grosset. The Eva pour la Vie association covered up to 50% of the cost of the purchase of laboratory equipment (in the amount of € 9,000) necessary for the smooth running of this work.

Epidemiological research

If the development of therapeutic routes adapted to the child is essential (to try to save the children who today, remain without a therapeutic solution and / or to reduce the side effects), we do not forget an equally strong reality: over the past 50 years, the number of children affected by cancer has never declined. Much remains to be done in terms of prevention, both in terms of research and regulation. Eva pour la vie is actively involved by co-financing environmental studies. The first of these, HAPPI, aimed to have the KUDZU SCIENCE laboratory analyze dust samples taken in homes bordering vines - welcoming children or pregnant women - as well as in a primary school classroom.

Andre Cicolella (RES, Paris)

André Cicolella is a French chemist, toxicologist and researcher in environmental health, specialist in health risk assessment. Eva pour la vie co-financed, with the REGARDS collective, the French transposition of a study carried out in Denmark from cancer and drug consumption registers, which had highlighted a risk multiplied by 3 of osteosarcomas and by 2 of Hodgkin's and non-Hodgkin's lymphomas in the event of exposure via drugs using DEP phthalate (DiEthyl Phthalate) in gastro-resistant drugs.